Cumulative pemetrexed dose increases the risk of nephrotoxicity

Pemetrexed is widely used as an anti-folate cytostatic agent for the treatment of non-small cell lung cancer (NSCLC), mesothelioma and thymoma. [1 –5] Dependent on treatment indication, therapy generally exists of four cycles of induction therapy with pemetrexed and a platinum-agent, which can be combined with the recently approved programmed death-ligand 1 (PD-L1) targeting monoclonal antibody pembrolizumab [6]. Pemetrexed - and, if applica ble, pembrolizumab - can be continued as maintenance treatment following the induction period [3,6].

Source: Lung Cancer - May 19, 2020 Category: Cancer & Oncology Authors: N. de Rouw, R.J. Boosman, H. van de Bruinhorst, B. Biesma, M.M. van den Heuvel, D.M. Burger, L.B. Hilbrands, R. ter Heine, H.J. Derijks Source Type: research